Use case: A Patient-centric Approach to Clinical Trial Site Selection

This illustrative use case shows how Citeline's integrated datasets (Sitetrove, Trialtrove, Pharmaprojects, Protocol SmartDesign, Investigator SmartSelect) support site selection for IgA nephropathy (IgAN) trials, where "80% of patients are diagnosed between ages 16 and 35" amid a competitive landscape of "17 ongoing phase three studies." The approach maps roughly 8,000 IgAN patients across the US and matches them to qualified investigators, referencing trials averaging 282 subjects over 24 months with an "enrollment rate of only 1.31 patients per site per month." It is framed as a methodology illustration rather than a single named client's results.

The customer is anonymised in Norstella’s own case study — not withheld by us.

Norstella is a holding company merging several pharma-intelligence brands — Citeline (trial intelligence), Evaluate (forecasting), MMIT (payer/formulary data) and Panalgo (real-world analytics) — into one data asset.

This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.